ArticleDiscover oncology2025
A differential diagnostic model based on immunological evaluation and routine laboratory tests: distinguishing multiple myeloma from other disorders with aberrant immunoglobulin elevation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Routine Laboratory-Based Machine Learning for Discriminating Multiple Myeloma from Clinical Mimickers: Development and Internal Validation of a Diagnostic Prediction Model.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveDevelop a diagnostic model using common hematological and immunological indicators to assist in the early screening and differential diagnosis of Multiple Myeloma (MM) in clinical settings, reducing the risk of misdiagnosis.
methodsA retrospective analysis was conducted on 274 newly diagnosed and treated MM patients and 137 connective tissue disease patients treated at Zhejiang Provincial People's Hospital from January 2008 to August 2023. Laboratory indicators, including complete blood count, biochemistry, coagulation function, and immunoglobulin markers, were collected. The cohort was randomly divided into a 70% training set and a 30% validation set. Relevant variables were selected through univariate and multivariate analyses in the training set. A discriminative diagnostic model was developed using a multivariate logistic regression algorithm. The model's predictive accuracy and generalizability were evaluated by validating and conducting receiver operating characteristic (ROC) curves and calibration curves.
resultsThe developed differential diagnostic model in this study included the following observed indicators: IgM, glomerular filtration rate, high-density lipoprotein, red cell distribution width, and thrombin time. The model demonstrated excellent discriminatory power and good calibration, with an area under the curve (AUC) value of 0.980 (95% CI: 0.967-0.994). Additionally, the model exhibited high sensitivity (0.963), specificity (0.938), accuracy (0.955). The validation set further confirmed the generalization and accuracy of the model, with an AUC value of 0.954 (95% CI: 0.961-0.992).
conclusionsThe constructed differential diagnostic model in this study can accurately predict and differentiate MM patients and those with elevated Ig abnormalities, thereby enhancing the efficiency of clinical diagnostic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.